AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 251 min read$CAPR

Bergmann Anthony sold $27K of CAPR

Bergmann Anthony (CHIEF FINANCIAL OFFICER) sold 900 shares of CAPRICOR THERAPEUTICS, INC. (CAPR) at $30.00 across 2 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bergmann Anthony
Published Jun 25, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CAPR
Neutral
medium confidence
Mentioned
$CAPR
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAPRNeutralLow
01

Why it matters

The CFO’s open-market sale under a pre-arranged 10b5-1 plan is typically treated as routine compliance activity rather than a fundamental change signal.

02

Market read

Traders may monitor insider activity for sentiment, but the disclosed transaction size and 10b5-1 structure suggest limited incremental impact.

03

What to watch

The article provides only the sale details; it does not include any concurrent buy transactions, changes in guidance, or operational catalysts that would make the sale more decision-relevant.

Relevance 2/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-24 (covers sales 2026-06-22 to 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Capricor Therapeutics, Inc.

Company-level read

Ticker impact

$CAPRNeutralMedium confidence
Context

Capricor Therapeutics CFO Bergmann Anthony sold 900 shares in open-market transactions at $30/share under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and a small dollar value ($27k), which typically reduces interpretive weight.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s near-term risk assessment, potentially affecting sentiment among retail holders.

Key entities

  • issuer
    CAPRICOR THERAPEUTICS, INC.

    Subject of the Form 4 insider transaction; CFO sold 900 shares at $30/share.

  • insider
    Bergmann Anthony

    Chief Financial Officer who executed the open-market sale(s) under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$CAPRMedAI 8/10

Why did CAPR, LKQ, PSKY Stocks Plunge To 52-Week Lows Today?

Capricor Therapeutics (CAPR) fell 36% to a 52-week low after an FDA advisory committee voted 9-3 against recommending Deramiocel approval, citing clinical evidence concerns. JonesResearch downgraded CAPR to Hold. LKQ dropped 14% to a six-year low after Q2 revenue and EPS missed estimates and guidance was cut. Paramount Skydance (PSKY) slid 2% on ongoing legal issues around its Warner Bros. Discovery deal.

stocktwits.com4 min
JUL 30
$CAPRMedAI 8/10

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics (NASDAQ: CAPR) said the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 (0 abstain) that available evidence does not support Deramiocel’s effectiveness for cardiomyopathy in Duchenne muscular dystrophy. The vote is non-binding and focused on a narrower indication than Capricor proposed. Capricor targets an Aug. 22, 2026 PDUFA action date.

finanznachrichten.de4 min
JUL 30
$CAPRHighAI 9/10

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

Capricor Therapeutics’ Deramiocel for Duchenne muscular dystrophy fell after an FDA advisory panel voted 9-3 that the company did not provide sufficient evidence of effectiveness. FDA staff cited lack of substantial evidence from Study HOPE-3 and no significant differences vs placebo in HOPE-2. Capricor noted The Lancet published HOPE-3 results. Shares were down 52.36% to $3.13.

benzinga.com4 min
JUL 30
$CAPRMed

Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more

An FDA advisory panel voted 9-3 against effectiveness data for Capricor Therapeutics’ Duchenne muscular dystrophy treatment, according to STAT. The panel focused on whether it could treat Duchenne-related cardiomyopathy. The FDA previously declined approval and requested more data, and during the meeting criticized changes to the study’s statistical analysis plan.

statnews.com2 min
JUL 30
$MSFTMed

Microsoft rally offsets Fed jitters; Quanta, Huntington Ingalls gain By Investing.com

U.S. stock index futures rose as Microsoft rallied after a fiscal Q4 2026 earnings beat, with revenue of $90.01B (+18% YoY) and non-GAAP EPS of $4.74. Quanta Services and Huntington Ingalls also gained on better-than-expected results and contract updates. Meta fell after earnings; other movers included Check Point, Capricor, Align, Hyatt, Sirius XM, Trinity, and ImmunityBio.

investing.com5 min